NASDAQ$LUNG
Pulmonx Corporation · Q2 2024 earnings
Q2 2024 earnings · · Investor relations
Briefing
Reported record worldwide revenue with increased U.S. revenue and a stable gross margin.
Pulmonx reported record worldwide revenue of $20.8 million for Q2 2024, a 21% increase year-over-year. U.S. revenue grew by 26% to $13.9 million. The company maintained a gross margin of 74%.
- Achieved record worldwide revenue of $20.8 million, a 21% increase year-over-year.
- U.S. revenue reached $13.9 million, a 26% increase year-over-year.
- Gross margin remained stable at 74%.
- Added 17 new Zephyr Valve U.S. treatment centers.
Headline financials
Revenue & EPS history
Pulmonx · Revenue · Quarterly
$20.8M
Forward guidance
Pulmonx continues to expect revenue for the full year 2024 to be in the range of $81 million to $84 million. The Company continues to expect gross margin for the full year 2024 to fall within the range of 74% to 75%. Pulmonx continues to expect total operating expenses for the full year 2024 to fall within the range of $127 million to $129 million, inclusive of approximately $25 million of non-cash stock-based compensation.
Tailwinds
- Revenue for the full year 2024 expected to be in the range of $81 million to $84 million.
- Gross margin for the full year 2024 expected to fall within the range of 74% to 75%.
- Commercial strategy demonstrating positive momentum.
- Expanding presence by opening new accounts.
- Preparing to launch new pilot programs to optimize patient workflows.
Headwinds
- Total operating expenses for the full year 2024 expected to fall within the range of $127 million to $129 million.
- Includes approximately $25 million of non-cash stock-based compensation.
- Net loss in the second quarter of 2024 was $15.3 million.
- Adjusted EBITDA loss in the second quarter of 2024 was $7.6 million
- One-time, non-cash charge of $1.7 million to impair internally developed software
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2024
-3.4%
Avg return
Earnings day
-4.1%
Avg return
5 days after
-5.3%
Avg return
30 days after
42%
10 / 24 earnings
Positive
+32.2%
Q4 2024
Best reaction
-64.7%
Q3 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -1.5% | -6.7% | +12.6% | |
| Q4 2025 | +0.6% | -6.1% | -28.2% | |
| Q3 2025 | -18.9% | -28.6% | +29.1% | |
| Q1 2025 | -21.9% | -28.8% | -29.6% | |
| Q4 2024 | +32.2% | +30.7% | +17.0% | |
| Q3 2024 | -7.7% | +5.2% | -4.7% | |
| Q2 2024 | -8.1% | -15.4% | +3.7% | |
| Q1 2024 | +23.3% | +21.9% | -4.7% | |
| Q4 2023 | -17.7% | -27.9% | -36.1% | |
| Q3 2023 | +6.9% | +20.7% | +34.2% | |
| Q2 2023 | -4.1% | -8.0% | -26.0% | |
| Q1 2023 | +1.1% | -0.2% | -1.5% | |
| Q4 2022 | +20.8% | +26.0% | +27.1% | |
| Q3 2022 | -64.7% | -61.1% | -52.3% | |
| Q2 2022 | +9.2% | +19.9% | +5.7% | |
| Q1 2022 | +0.6% | -23.6% | -23.9% | |
| Q4 2021 | -6.9% | -2.5% | -12.5% | |
| Q3 2021 | +7.1% | +12.6% | -23.7% | |
| Q2 2020 | -7.6% | -10.9% | -1.6% | |
| Q2 2021 | +0.1% | +6.0% | +3.3% | |
| Q1 2020 | -5.8% | -5.3% | +9.9% | |
| Q1 2021 | -8.7% | -9.6% | -10.3% | |
| Q4 2020 | -4.1% | -3.4% | -20.2% | |
| Q3 2020 | -4.9% | -3.4% | +5.6% | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro